BioCentury
ARTICLE | Company News

Protein'eXpert, Stallergenes deal

December 17, 2007 8:00 AM UTC

The partners began a double-blind, active- and placebo-controlled, Scandinavian Phase III trial designed to assess non-inferiority of 10 or 20 mg daily doses of oral balaglitizone versus 45 mg daily o...